Heidelberg Pharma AG · XETR:HPHA
Heidelberg Pharma — Investor Presentation (November 2018)
31 slides from Heidelberg Pharma's investor presentation, Nov 19, 2018
Slide 1: ATACs fighting Cancer
ATACs fighting Cancer November 2018
Slide 2: Safe Harbor
Safe Harbor Forward looking statements This communication contains certain forward-looking additional funding, risks of product liability and limitations of statements, relating to the Company’s business, which can be insurance, limitations of supplies, competition from other identified by the use o
Slide 3: Corporate Overview
Corporate ATAC ATAC Proprietary Financials & Overview Technology Business ATAC Project Outlook Platform Model HDP-101 © Heidelberg Pharma AG 3
Slide 4: Heidelberg Pharma at a Glance
Heidelberg Pharma at a Glance Developing new options to address major challenges in cancer therapy Our Company Our Mission Our Approach Listed as Heidelberg Pharma AG Improve efficacy New mode of action in cancer Frankfurt Stock Exchange: WL6 therapy - Antibody Targeted Overcome resistance Amanitin
Slide 5: Management Team with Strong Pharma and R&D Experience
Management Team with Strong Pharma and R&D Experience Dr. Jan Prof. Dr. Schmidt- Andreas Brand Pahl CEO / CFO CSO @ Heidelberg Pharma since 2001 @ Heidelberg Pharma since 2012 20 years’ experience in commercial and financial 20 years’ experience in research and higher education leadership positions
Slide 6: Strategic Cornerstones
Strategic Cornerstones Additional upside potential Build proprietary ATAC Sign technology licensing with partnered non-ATAC pipeline collaborations legacy clinical assets Proprietary lead candidate ATAC technology partnering HDP-101 with pharma and biotech ATAC Lead ATAC technology HDP-101 partner A
Slide 7: Achievements of Last 12 Months
Achievements of Last 12 Months Proprietary ATAC Project ATAC Technology Licensing Licensed Projects Development HDP-101 • Amanitin GMP transfer Amanitin synthesis • Multi-Target Research and • TLX250 - Diagnostic for • BCMA Antibody Option Agreement Renal Cancer with PET/CT GMP material Deal s
Slide 8: ATAC Technology Platform
Corporate ATAC ATAC Proprietary Financials & Overview Technology Business ATAC Project Outlook Platform Model HDP-101 © Heidelberg Pharma AG 8
Slide 9: Innovative Potential First-in-humans Mode of Action with Compelling Clinical Potential
Innovative Potential First-in-humans Mode of Action with Compelling Clinical Potential Unique mode of action of Amanitin as toxic payload… • Amanitin kills dividing AND quiescent tumor cells by binding and inhibiting RNA polymerase II Death cap mushroom …results in potential clinical benefits by Che
Slide 10: Antibody Drug Conjugate Technology – Proven & Established Technology
Antibody Drug Conjugate Technology – Proven & Established Technology ADC: Combining the best of two therapeutic modalities An body specificity + toxin efficacy → improved therapeu c window and fewer side effects © Heidelberg Pharma AG 10
Slide 11: Amanitin Compared Favorably to Approved ADC Toxins
Amanitin Compared Favorably to Approved ADC Toxins Calicheamicin Auristatin Maytansinoids Amanitin Target DNA Tubulin Tubulin RNA Pol II Target concentration ? 10-5 M 10-5 M 10-8 - 10-9 M Structure hydrophobic hydrophobic hydrophobic hydrophilic Activity on low low low high non-dividing cells Activi
Slide 12: ATACs – Highly Potent Payload, Superior to Existing Payloads
ATACs – Highly Potent Payload, Superior to Existing Payloads Complete remissions in JIMT-1 xenograft models after single dose application of 2.9mg/kg Her2-ATAC Clinical dose of T-DM1 ineffective (FDA approved Kadcyla®) Equivalent dose of Her2-ATAC shows complete remission Kadcyla could not achieve r
Slide 13: ATAC Business Model
Corporate ATAC ATAC Proprietary Financials & Overview Technology Business ATAC Project Outlook Platform Model HDP-101 © Heidelberg Pharma AG 13
Slide 14: Early Validation and Cash Through Pharma Collaborations + Future High Value Potential
Early Validation and Cash Through Pharma Collaborations + Future High Value Potential with Proprietary Portfolio Partnering target by target Antibodies from partners, license to the partner, development by the partner A A A A Defined payload ATAC toolbox: Linker variations customized and target-opti
Slide 15: Multi-Target Research and Option Agreements with Takeda and Magenta
Multi-Target Research and Option Agreements with Takeda and Magenta Research & Option Agreements Financials • Synthesis of ATACs using antibodies from the • Upfront technology access fees and R&D support Takeda/Magenta portfolio • Option fee for each option exercised • Both companies have exclusive
Slide 16: ATACs – Growing Pipeline of Proprietary and Partnered Programs
ATACs – Growing Pipeline of Proprietary and Partnered Programs Additional proprietary ATACs in research and preclinical development • Targets: PSMA, CD19, others • Excellent preclinical efficacy in mice and very good tolerability in cynomolgus monkeys Product Target Indication Research Preclinic Cli
Slide 17: Proprietary ATAC HDP-101
Corporate ATAC ATAC Proprietary Financials & Overview Technology Business ATAC Project Outlook Platform Model HDP-101 © Heidelberg Pharma AG 17
Slide 18: Multiple Myeloma – Major Unmet Medical Need
Multiple Myeloma – Major Unmet Medical Need • Second most prevalent hematopoietic malignancy* • MM represents about 0.8-1% of all cancers worldwide, with 70,000 deaths annually; median age at diagnosis is 65-70 years • Malignancy characterized by the proliferation of single clone of plasma cells der
Slide 19: BCMA Validated Target – Pipeline Overview
BCMA Validated Target – Pipeline Overview ADCs targeting BCMA – small competitive environment GSK: BCMA-MMAE ADC, Phase II data presented @ASH 12/2017: Overall response rate of 60% HDP-101: IND in preparation, 1st patient-in H2 2019 Celgene / Sutro collaboration: IND submission expected early
Slide 20: HDP-101 – Results from Research Collaboration with Heidelberg University and the DKFZ
HDP-101 – Results from Research Collaboration with Heidelberg University and the DKFZ Presented at ASH Comparison with MMAF (Auristatin Conjugate as used by GSK) on MM Patient Cells • Green lines: Non-dividing (quiescent) cells isolated from multiple myeloma patient bone marrow biopsies • Black line
Slide 21: Poor prognosis for MM Patients with 17p Deletion
Literature confirms: Poor prognosis for MM Patients with 17p Deletion www.bloodjournal.org on November 17, 2018 17p Deletion 17p Deletion © Heidelberg Pharma AG
Slide 22: Joint Publication with MDA in Nature in April 2015
Joint Publication with MDA in Nature in April 2015 17p Deletion = Loss of TP53/POLR2A on chromosome 17 © Heidelberg Pharma AG 22
Slide 23: 17p Deletion: Loss of TP53/POL2RA on chromosome 17
17p Deletion: Loss of TP53/POL2RA on chromosome 17 • NATURE Publication: 10 x increased susceptibility to Amanitin in the case of loss of POLR2A • POLR2A potential biomarker to increase therapeutic window Target of amanitin POLR2A close to TP53 on Chr 17 Passenger deletion © Heidelberg Pharma AG 2
Slide 24: Biomarker Applies to HDP-101 in Multiple Myeloma
Biomarker Applies to HDP-101 in Multiple Myeloma Oral Presentation at the ASH 60th Annual Meeting Dec. 2018 in San Diego The University of Texas MD Anderson Cancer Center, Houston, TX, USA, and Heidelberg Pharma AG: Translates basic findings from NATURE article to Multiple Myeloma HDP-101 is active
Slide 25: Clinical Hypothesis Around 17p Deletion
Clinical Hypothesis Around 17p Deletion • Multiple Myeloma patients with 17p deleted tumors have a very high medical need for new treatment options • HDP-101 has a preferential activity on 17p deleted tumor cells derived from Multiple Myeloma patients (ASH conference 2018) • Potential options to spe
Slide 26: Financials & Outlook
Corporate ATAC ATAC Proprietary Financials & Overview Technology Business ATAC Project Outlook Platform Model HDP-101 © Heidelberg Pharma AG 26
Slide 27: Financials
Financials Guidance Revised Guidance in € m FY 2017 9M 2018 03/2018 10/2018 Sales revenue and other income 2.5 3.5 3.0 to 5.0 3.5 to 4.5 Operating expenses 13.2 10.9 16.0 to 20.0 14.0 to 16.0 Operating result (EBIT) -10.8 -7.4 -12.0 to -16.0 -10.0 to -12.0 Funds required 8.6* 7.7* 13.0 to 17.0 10.0
Slide 28: Heidelberg Pharma Shares
Heidelberg Pharma Shares Share performance 2018 Share ownership as of 15 November 2018 • High: €3.980 (15 January 2018) Corporate bodies * • Low: €1.880 (11 October 2018) 1% • Daily trading volume: 30,414 shares (2017: 14,049) Freefloat 20% • Shares outstanding: 28,131,385 (as of 15 November 2018) •
Slide 29: Next Steps and Potential Milestones
Next Steps and Potential Milestones ATAC technology and proprietary pipeline Partnered legacy clinical programs • HDP-101 REDECTANE® • Telix Phase III recruitment in • Start of GLP toxicity study for HDP-101 Australia • Clinical Trial Application Q2/2019 • Initiation of Phase III trial in Europe sub
Slide 30: Investment Summary
Investment Summary Developing new options to address major challenges in cancer therapy • Heidelberg Pharma is developing new treatment options with Amanitin for different cancer indications, also validated by high quality collaborations • The innovative first in humans mode of action provides high
Slide 31: Contact Us
Contact Us Upcoming conferences & events H1 2019 Venue Date 60th ASH Annual Meeting & Exposition San Diego 01 – 04 December 2018 JP Morgan Annual Healthcare Conference San Francisco 07 – 09 January 2019 PepTalk: The Protein Science Week San Diego 14 – 18 January 2019 9th Annual World ADC London 04 –
Heidelberg Pharma — Investor Presentation (November 2018) on 6ix